| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-8703(03)00226-6 |
| P698 | PubMed publication ID | 12891182 |
| P50 | author | Charles H Hennekens | Q89527500 |
| P2093 | author name string | Eran Leitersdorf | |
| Karen Meir | |||
| P2860 | cites work | Inhibition of human polymorphonuclear leukocyte functions by ibuprofen | Q70175195 |
| Reduction of atherosclerosis with nonsteroidal anti-inflammatory drugs | Q70552255 | ||
| Effects of naproxen and methotrexate on the extent of aortic lesions and cholesterol concentrations in cholesterol-fed rabbits | Q71435795 | ||
| Clinical and research challenges in risk factors for cardiovascular diseases | Q73173152 | ||
| Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice | Q73288555 | ||
| Ibuprofen inhibits adhesiveness of monocytes to endothelium and reduces cellular oxidative stress in smokers and non-smokers | Q73293036 | ||
| Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women | Q73940124 | ||
| Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries | Q74172635 | ||
| The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis | Q77542530 | ||
| Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65 | Q78121965 | ||
| Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin | Q78162510 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Platelet-active drugs : the relationships among dose, effectiveness, and side effects | Q28175147 | ||
| Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 | ||
| Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib | Q28191367 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| Nonsteroidal antiinflammatory drugs after acute myocardial infarction | Q28192441 | ||
| Role of prostacyclin in the cardiovascular response to thromboxane A2 | Q28192832 | ||
| Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study | Q28193363 | ||
| Anti-inflammatory effects of aspirin and sodium salicylate | Q28193369 | ||
| Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice | Q28193681 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Atherosclerosis. the road ahead | Q29618972 | ||
| Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 | ||
| Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors | Q34432988 | ||
| Immune mechanisms in atherosclerosis | Q34462668 | ||
| Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice | Q34730034 | ||
| Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins. | Q36438422 | ||
| Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease | Q38695089 | ||
| Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors | Q40864231 | ||
| Ibuprofen: new explanation for an old phenomenon | Q40980462 | ||
| The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture | Q41010478 | ||
| Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase | Q41375412 | ||
| Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials | Q41535803 | ||
| Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris | Q43493913 | ||
| Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering | Q43516483 | ||
| Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site | Q43625666 | ||
| The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease | Q44175663 | ||
| Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 | ||
| Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. DAVIT Study Group. Danish Verapamil Infarction Trial. | Q50563067 | ||
| The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. | Q54019410 | ||
| Protective Role of Interleukin-10 in Atherosclerosis | Q58150380 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 199-202 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | American Heart Journal | Q2227156 |
| P1476 | title | Inflammation in atherosclerosis: causal or casual? The need for randomized trials | |
| P478 | volume | 146 |
Search more.